Omacor, 1 g capsules 28 pcs

Omacor decreases triglycerides as a result of decreasing the concentration of LDL-C, in addition, it actively affects hemostasis by reducing the synthesis of thromboxane A2 and slightly increasing the clotting time.

It inhibits the synthesis of triglycerides in the liver because EPA and DHA inhibit the esterification of other fatty acids. A decrease in free fatty acids (increased fatty acid beta-oxidation peroxisomes) involved in triglyceride synthesis also contributes to the decrease in triglyceride levels.

The increase in HDL is very small and not permanent. It is significantly less than after taking fibrates.

The results of observational studies (over 3.5 years) of patients taking 1 g of Omacor daily showed a significant reduction in the combined index including all-cause mortality as well as nonfatal myocardial infarction and stroke.

Pharmacokinetics

There are 3 major pathways for their metabolism during and after absorption of omega-3 fatty acids:

The fatty acids are first delivered to the liver, where they are incorporated into various categories of lipoproteins and sent to peripheral lipid stores;

– phospholipids of cell membranes are replaced by phospholipids of lipoproteins, after which fatty acids act as precursors to various eicosanoids;

– most fatty acids are oxidized to provide energy needs.

The concentration of omega-3 class fatty acids, EPA and DHA, in plasma phospholipids corresponds to the concentration of EPA and DHA included in cell membranes.

Indications

Composition

How to take, the dosage

Ingestion, together with food. For secondary prevention of myocardial infarction it is recommended to take 1 capsule per day.

The duration of treatment is according to the doctor’s recommendation.

Hypertriglyceridemia: the initial dose is 2 capsules per day.

In case of lack of therapeutic effect it is possible to increase the dose to 4 capsules per day.

The duration of treatment is according to the doctor’s recommendation.

Interaction

In concomitant use with oral anticoagulants, there is a risk of increased bleeding time. Administration of Omacor together with warfarin does not lead to any hemorrhagic complications.

Special Instructions

Due to a moderate increase in bleeding time (when taking a high dose of 4 capsules), monitoring of patients on anticoagulant therapy is required, and if necessary, appropriate adjustment of the anticoagulant dose. This therapy does not preclude the need for routine monitoring in the treatment of such patients.

The increase of bleeding time in patients with increased risk of hemorrhage (as a result of severe trauma, surgery, etc.) should be taken into account. The available experience in the study of secondary endogenous hypertriglyceridemia (especially uncontrolled diabetes mellitus) is very limited.

There is no clinical experience with the treatment of hypertriglyceridemia in combination with fibrates. When taking Omacor, there may be a moderate increase in “hepatic” transaminase activity.

In patients with impaired liver function (especially when taking a high dose – 4 capsules) regular monitoring of liver function (AST and ALT) is required. There are no data on the use of Omacor in children, elderly patients over 70 years of age or in patients with hepatic impairment. No dose adjustment is required in patients with impaired renal function.

Contraindications

With caution:

Side effects

Infectious processes: infrequent – gastroenteritis.

Immune system disorders: infrequent – hypersensitivity.

Disorders of metabolism and nutrition: rarely – hyperglycemia.

Nervous system disorders: infrequent – dizziness, dysgeusia (perversion of taste); rarely – headache.

vascular disorders: very rare – BP lowering.

Respiratory, thoracic and mediastinal organs: very rare – dry nose.

Gastrointestinal disorders: frequently – dyspepsia, nausea; infrequently – abdominal pain, gastrointestinal disorders, gastritis, pain in the upper abdomen; very rarely – bleeding from the lower GI tract.

Liver disorders: rarely – liver function disorders.

Skin and subcutaneous fatty tissue: rarely – acne, itching rash; very rarely – urticaria.

In studies: very rare increased number of blood leukocytes, blood lactate dehydrogenase were noted. In patients with hypertriglyceridemia, a moderate increase in transaminases (AST, ALT) was reported.

Anecdotal side effects have been reported.

Metabolic and nutritional disorders: increased need for insulin (need to increase the standard dose).

Hepatic disorders: increased activity of liver enzymes.

Skin and subcutaneous tissue disorders: pink acne, rash, redness/erythema, urticaria in the chest, neck and shoulders.

Overdose

Symptoms: side effects may occur or increase in severity.

Treatment: symptomatic therapy.

Pregnancy use